Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BDB 1

Next Previous
Drug Profile

BDB 1

Alternative Names: BDB-001 - Beijing Defengrei Biotechnology; BDB-001 injection; BDB-1

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Defengrei Biotechnology
  • Developer Beijing Defengrei Biotechnology; Staidson Beijing BioPharmaceuticals
  • Class Anti-inflammatories; Antivirals; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Complement C5a inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III COVID 2019 infections
  • Phase II Hidradenitis suppurativa
  • Phase I/II Anti-neutrophil cytoplasmic antibody-associated vasculitis

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in China (IV, Infusion)
  • 20 May 2024 Staidson Beijing Biopharmaceuticals and Beijing Defengrui Biotechnology terminates a phase I trial for COVID-2019 infections in China due to the COVID-19 epidemic situation (IV) (NCT05075304)
  • 20 May 2024 Staidson Beijing BioPharmaceuticals terminates the phase II/III trial in COVID-2019 infections
    due to the COVID-19 epidemic situationin Bangladesh, China, India, Indonesia and Spain (IV) (NCT04449588)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top